E. Kneepkens

Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up

E. Kneepkens, James Cheng‐Chung Wei, Michael T. Nurmohamed et al. · Annals of the Rheumatic Diseases · 2013 · 88 citations

Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-up

Erik H Vogelzang, E. Kneepkens, Michael T. Nurmohamed et al. · Annals of the Rheumatic Diseases · 2014 · 79 citations

Medication-Related Hospital Readmissions Within 30 Days of Discharge: Prevalence, Preventability, Type of Medication Errors and Risk Factors

Elien B. Uitvlugt, Marjo J. A. Janssen, C. E. H. Siegert et al. · Frontiers in Pharmacology · 2021 · 71 citations · Full text

Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up

E. Kneepkens, C. Krieckaert, Desirée van der Kleij et al. · Annals of the Rheumatic Diseases · 2014 · 61 citations

Capillary Blood Microsampling to Determine Serum Biopharmaceutical Concentration: Mitra ^® Microsampler vs Dried Blood Spot

Karien Bloem, Tiny Schaap, Ronald S. Boshuizen et al. · Bioanalysis · 2018 · 52 citations